Prostate Cancer
Conditions
Brief summary
This is a single arm phase II study of image-guided pencil beam scanning proton SBRT (40Gy RBE in 5 fractions delivered every other day) for patients with low- and intermediate-risk prostate cancer. The primary aim is to assess GU/GI toxicity of proton SBRT and compare this to historic outcomes associated with photon-based prostate SBRT. The primary endpoint is 2-year grade 3+ GU/GI toxicity free rate by CTCAE v5.0, which is expected to be ≥95%. Toxicity will be evaluated by the treating radiation oncologist at least once during SBRT, then following SBRT at 1, 3, 6, 12, 18, and 24 months. The treatment will be considered safe if grade 3 or higher GU/GI toxicity free rate at 2 years is \>85% (95% rate expected with a 10% non-inferiority margin). The accrual goal is 61 patients over 3 years. To ensure that unexpected significant toxicity is identified, all grade 3 or higher toxicities will be reported to the study PI and the trial will stop accruing if at any point 4 or more patients experience a grade 3 or higher toxicity after completing SBRT. This is felt to be conservative given the vast experience with photon SBRT at this dose with an expected G3+ toxicity of \ 5%. Secondary objectives are to examine patient-reported urinary, gastrointestinal, sexual, and financial outcomes using IPSS, EPIC-26, and COST questionnaires at the same follow-up timepoints as above. Baseline measures of these domains will be obtained prior to treatment as well. Clinical outcomes will also be evaluated with PSA measured at each follow-up, as well as prostate MRI and biopsies at 2 years. Patients will be followed for at least 2 years to determine rates of PSA relapse, salvage treatment, development of metastases, death from prostate cancer, and overall survival. A dosimetric comparison will be performed where each patient will be planned for proton and photon SBRT to determine possible advantages of proton SBRT.
Interventions
RADIATIONPencil Beam Scanning Proton SBRT
The intervention being investigated is ultra-hypofractionated, image-guided, pencil beam scanning proton SBRT directed at the prostate gland and seminal vesicles to 40 Gy equivalent in 5 fractions, delivered every other day.
Sponsors
The New York Proton Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Biopsy-proven NCCN low- or intermediate-risk prostate cancer, which includes patients with: * Gleason score ≤7 disease * PSA ≤20 ng/ml * Clinical T1-T2c disease * Note: Patients who only have radiographic evidence of possible or probable T3 disease (i.e., extracapsular extension or seminal vesical invasion) will not be excluded. * KPS ≥ 80% * Prostate size as determined on MRI to be \< 100 cc. Prostate size can be determined on CT scan if MRI is not available. * Male 18 years of age or older * IPSS ≤ 20 * Patient must be a candidate for and agree to placement of intraprostatic fiducial markers and a hydrogel rectal spacer * Patient must be available for at least 2 years of follow-up
Exclusion criteria
* Prior prostate surgery (including cryosurgery) * Note: Patients who underwent TURP or greenlight PVP are eligible if it was \> 12 weeks prior to the anticipated start date of SBRT * Prior history of chronic prostatitis or urethral stricture * Currently active cancer(s) other than non-melanoma skin cancers. Patients are not considered to have currently active cancers if they have completed therapy and are considered by their physicians to be at \<5% risk of relapse within 2 years. * Life expectancy of \< 2 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 1. Grade 3+ GU/GI toxicity-free rate determined by CTCAE v5.0 grading. | 2 years | The NCI Common Terminology Criteria for Adverse Events v5.0 is a descriptive terminology which can be utilized for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE term. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 1. Patient reported urinary symptoms determined by IPSS. | 2 years | The International Prostate Symptom Score (IPSS) was developed to assess the severity of lower urinary tract symptoms associated to Benign Prostatic Hyperplasia and has also been applied to other conditions that cause LUTS. The IPSS consists of a total of seven questions that deal with voiding symptoms (incomplete empty, intermittency, weak stream and straining to void) and storage symptoms (frequency, urgency and nocturia) and an additional question to measure quality of life. The score ranges from 0 to 35, with lower scores denoting a better health state. |
| 2. Patient reported urinary, bowel, and hormonal quality of life determined by EPIC-26. | 2 years | EPIC-26 is the "Expanded Prostate Cancer Index Composite" patient reported outcomes questionnaire. A clinical tool to assess urinary, bowel, sexual and vitality health. The score from each of the 5 domains runs from 0 (none) to 12 (severe) impact on quality of life. Each domain score when added together gives an overall score of zero (unaffected) to 60 (severely affected) |
| 3. Patient reported financial toxicity determined by COST | 2 years | Comprehensive Score for Financial Toxicity Functional Assessment of Chronic Illness Therapy (COST-FACIT) was developed as part of a series of questionnaires aimed at measuring different symptom indexes of health-related quality of life in patients with advance disease such as cancer. The survey contains 12 questions and each of them is rated from 0 (not at all) to 4 (very much). This survey focuses on financial distress caused by illness in patients with cancer. It takes about 5 minutes to complete. |
| 4. 2-year and 5-year biochemical progression free survival | 2 years and 5 years | Biochemical failure is defined as a sustained rise in PSA of 2 ng/mL or more above the nadir (the lowest PSA level after radiotherapy). |
| 5. 2-year local control determined by MRI and biopsies | 2 years | — |
| 6. 2-year and 5-year metastasis free survival | 2 years and 5 years | — |
| 7. 2-year and 5-year prostate cancer specific survival | 2 years and 5 years | — |
| 8. 2-year and 5-year overall survival | 2 years and 5 years | — |
| 9. Dosimetric advantages determined by target coverage, conformality, and normal tissue sparing | 2 years | — |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORDaniel Gorovets, MD
The New York Proton Center
PRINCIPAL_INVESTIGATORShaakir Hasan, DO
The New York Proton Center
Outcome results
None listed